Statistik Asas
| LEI | 549300VYLRG6E7YKGJ44 |
| CIK | 1603469 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Innocoll Holdings plc
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 14, 2017 |
INNL / Innocoll Holdings plc / Camber Capital Management LLC - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Innocoll AG (Name of Issuer) American Depositary Shares, no par value (Title of Class of Securities) 47580Q103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2017 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 4, 2016 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File No. 001-36565 INNOCOLL AG (Translation of registrant?s name into English) Innocoll Holdings plc Unit 9, Block D Monksland Business Park Monksland, Athlone, Co. Ros |
|
| February 4, 2016 |
Innocoll Holdings 425 (Prospectus) Filed by Innocoll Holdings plc Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Innocoll AG Commission File Number: 001-36565 Submission of Matters to a Vote of Security Holders Results of Extraordinary General Meeting of Shareholders Innocoll AG (the ?Company?) held an Extraordinary General Meeting of Shareholders in Munich, Germany on January 30, 2016 to consider proposals related to the proposed cross-border merger between the Company and Innocoll Holdings plc, a public limited company formed under Irish law (?Innocoll Ireland?), with the Company being the disappearing entity and Innocoll Ireland being the surviving entity in a merger by acquisition (the ?Merger?). |
|
| December 24, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File No. 001-36565 INNOCOLL AG (Translation of registrant?s name into English) Innocoll Holdings plc Unit 9, Block D Monksland Business Park Monksland, Athlone, Co. Ro |
|
| December 24, 2015 |
EX-99.2 3 t1503027ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Unit 9, Block D Monksland Business Park Monksland, Athlone Co. Roscommon, Ireland Tel: + 353 (0)90 6486834 Fax: + 353 (0)90 6486835 www.innocollinc.com December 24, 2015 Re: Innocoll AG Extraordinary General Meeting, January 30, 2016 Dear Shareholder: Please find enclosed the Notice and Proxy Card inviting you to participate in the Innocoll AG |
|
| December 24, 2015 |
EX-99.1 2 t1503027ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Innocoll AG, Saal an der Donau - ISIN DE000A12UKR1 - - Securities identification number A12UKR and - ISIN DE000A14KT09 - - Securities identification number A14KT09 - Our shareholders are hereby invited to participate in the Extraordinary General Meeting scheduled for Saturday 30 January 2016 at 10 a.m. CET in the offices of Dr. Susanne Frank, |
|
| December 21, 2015 |
t1502996ex2-1 - none - 7.7117711s TABLE OF CONTENTS Exhibit 2.1? Merger Proposal ? ? COMMON CROSS-BORDER MERGER TERMS ? ? ? GRENZ?BERSCHREITENDER VERSCHMELZUNGSPLAN ? ? ? ? THE UNDERSIGNED ? ? ? DIE UNTERZEICHNETEN ? ? ? ? Innocoll Holdings PLC, ? ? ? Innocoll Holdings PLC, ? ? ? ? a public company limited by shares incorporated under and governed by the laws of Ireland which has its registered of |
|
| December 21, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File No. 001-36565 INNOCOLL AG (Translation of registrant’s name into English) Innocoll Holdings plc Unit 9, Block D Monksland Business Park Monksland, Athlone, Co. Ro |
|
| December 9, 2015 |
Innocoll Holdings FORM 425 (Prospectus) Filed by Innocoll AG pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Innocoll AG Commission file number: 001-36565 Innocoll AG Announces Plan to Move Corporate Domicile to Ireland ATHLONE, Ireland, December 9, 2015 — Innocoll AG (NASDAQ:INNL) today announced that its supervisory board has unanimously approved a plan to move the company’s legal domicile from Germany to Ireland. |
|
| November 12, 2015 |
INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS)/INCOME (UNAUDITED) Exhibit 99.2 INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS)/INCOME (UNAUDITED) Thousands of Euros (except share and share data) Notes Three months ended 09/30/2015 Three months ended 09/30/2014 Nine months ended 09/30/2015 Nine months ended 09/30/2014 Revenue 4 ? 594 ? 1,141 ? 1,779 ? 3,742 Cost of sales (1,122 ) (1,218 ) (3,656 ) (4,161 ) Gross loss (528 ) (77 ) (1,877 ) (41 |
|
| November 12, 2015 |
Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update EX-99.1 2 t1502625ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Innocoll AG Announces Third Quarter 2015 Financial and Operating Results and Corporate Update ATHLONE, Ireland, Nov. 11, 2015 — Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-b |
|
| November 12, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 t15026256k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Innocoll AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 notional value per share (Title of Class of Securities) 45780Q103 (CUSIP Number) Ron Carlson, Esq. NewSmith Opportunities Priva |
|
| October 9, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Park Monksland, Athlone Ireland |
|
| October 8, 2015 |
October 8, 2015 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Innocoll AG Registration Statement on Form F-3 Filed September 29, 2015 File No. 333-207184 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Innocoll AG (the ?Registrant?) hereby requ |
|
| October 8, 2015 |
Innocoll Holdings AMENDMENT NO. 1 TO FORM F-3 As filed with the U.S. Securities and Exchange Commission on October 8 , 2015 Registration No. 333- 207184 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant?s name into English) Federal |
|
| September 29, 2015 |
Exhibit 3.1 Satzung Articles of Association Convenience Translation I. ALLGEMEINE BESTIMMUNGEN I. GENERAL PROVISIONS ? 1 Section 1 Firma, Sitz Corporate Name, Registered Office 1. Die Gesellschaft f?hrt die Firma 1. The name of the Company is Innocoll AG. Innocoll AG. 2. Die Gesellschaft hat ihren Sitz in Saal an der Donau. 2. The Company has its registered office at Saal an der Donau. ? 2 Section |
|
| September 29, 2015 |
F-3 1 t1502231-f3.htm FORM F-3 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 29, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of registrant as specified in its charter) Not Applicable (Translation of registrant’s n |
|
| September 21, 2015 |
Corporate Presentation September 2015 MAKING BETTER HAPPEN Exhibit 99.1 Corporate Presentation September 2015 MAKING BETTER HAPPEN 2 l Forward Looking Statements Any statements in this presentation about our future expectations, plans and prospects, including statements about the development of our product candidates and the timing, conduct, enrollment and outcome of our clinical studies, the availability of data from those studies and other statements co |
|
| September 21, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 t15021986k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business |
|
| August 28, 2015 |
ANNUAL GENERAL MEETING 2015 OF INNOCOLL AG DECLARED VOTING RESULTS EX-99.1 2 t1502039ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ANNUAL GENERAL MEETING 2015 OF INNOCOLL AG DECLARED VOTING RESULTS Percentages are approximate values. AGENDA ITEM OBJECT OF RESOLUTION VALID VOTES CAST % OF SHARE CAPITAL YES-VOTES AND % OF VOTES CAST NO-VOTES AND % OF VOTES CAST ABSTENTIONS AND % OF VOTES CAST PROPOSAL 2 Discharge of the Management Board 1,420,464 79.29% 1,391,708 (97.98%) ( |
|
| August 28, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 t15020396k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Pa |
|
| August 14, 2015 |
INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS (UNAUDITED) Exhibit 99.2 INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS (UNAUDITED) Thousands of Euros (except share and share data) Notes Three months ended 06/30/2015 Three months ended 06/30/2014 Six months ended 06/30/2015 Six months ended 06/30/2014 Revenue 4 ? 569 ? 1,316 ? 1,185 ? 2,601 Cost of sales (1,168 ) (1,391 ) (2,534 ) (2,943 ) Gross loss (599 ) (75 ) (1,349 ) (342 ) Researc |
|
| August 14, 2015 |
Exhibit 99.1 Innocoll AG Announces Second Quarter 2015 Financial and Operating Results and Updates Late-Stage Product Portfolio Progress ATHLONE, Ireland, Aug. 14, 2015 ? Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technol |
|
| August 14, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 t15019066k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Pa |
|
| July 16, 2015 |
Exhibit 99.1 Innocoll AG, Saal an der Donau - ISIN DE000A12UKR1 - - Securities identification number A12UKR and - ISIN DE000A14KT09 - - Securities identification number A14KT0 - Our shareholders are hereby invited to participate in the Annual General Meeting scheduled for Monday 24 August 2015 at 14:00 CET in the offices of Dr. Susanne Frank, Residenzstra?e 27, 80333 Munich, Germany I. Agenda 1. P |
|
| July 16, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Park Monksland, Athlone Ireland (A |
|
| July 8, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Park Monksland, Athlone Ireland (A |
|
| May 14, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) 6-K 1 t15011586k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Park |
|
| May 14, 2015 |
Innocoll AG Announces First Quarter Financial and Operating Results Exhibit 99.1 Innocoll AG Announces First Quarter Financial and Operating Results ATHLONE, Ireland, May 14, 2015 ? Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results fo |
|
| May 8, 2015 |
INNL / Innocoll Holdings plc / MORGAN STANLEY - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) INNOCOLL AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary |
|
| May 4, 2015 |
INNL / Innocoll Holdings plc / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Innocoll AG (Name of Issuer) American Depositary Shares, no par value (Title of Class of Securities) 47580Q103 (CUSIP Number) April 24, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| May 4, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated May 4, 2015 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| April 27, 2015 |
3,321,669 American Depositary Shares t1500945-424b4 - none - 21.4041402s TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration No. 333-203362? 3,321,669 American Depositary Shares Representing 250,692 Ordinary Shares ? Innocoll AG ? ? ? $9.00 per American Depositary Share ? ? Innocoll AG, a German stock corporation, is offering 1,999,690 American Depositary Shares, or ADSs, and the selling shareholders identified in this |
|
| April 23, 2015 |
Innocoll Holdings AMENDMENT NO. 3 TO FORM F-1 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 23, 2015 Registration No. 333-203362 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into E |
|
| April 22, 2015 |
EX-1.1 2 t1500925ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 INNOCOLL AG Registered Ordinary Shares in the form of American Depositary Shares (each representing 1/13.25 of an Ordinary Share, no par value, with a notional par value of €1.00 per Ordinary Share) UNDERWRITING AGREEMENT , 2015 PIPER JAFFRAY & CO. As the Representative of the several Underwriters listed in Schedule I hereto c/o Piper Jaffray & Co |
|
| April 22, 2015 |
Innocoll Holdings AMENDMENT NO. 2 TO FORM F-1 t1500925-f1a - block - 2.4922492s ? As filed with the U.S. Securities and Exchange Commission on April 22, 2015 Registration No. 333-203362? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? INNOCOLL AG (Exact name of Registrant as specified in its charter) ? Not Applicable (Translatio |
|
| April 22, 2015 |
EX-10.10 5 t1500925ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 Phantom Share Award Agreement between 1. Innocoll AG registered with the commercial register of the local court of Regensburg under HRB 14298, (the “Company”), and 2. [Name, address] (the “Grantee”). The Company and the Grantee are each hereinafter individually referred to as a “Party” and together also as the “Parties”. Section 1 Prelimin |
|
| April 20, 2015 |
Innocoll Holdings AMENDMENT NO. 1 TO FORM F-1 t1500869-f1a - block - 19.081908s TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 20, 2015 Registration No. 333-203362? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? INNOCOLL AG (Exact name of Registrant as specified in its charter) ? Not Applic |
|
| April 10, 2015 |
t1500775-f1 - none - 23.4101964s TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 10, 2015 Registration No. 333- ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? INNOCOLL AG (Exact name of Registrant as specified in its charter) ? Not Applicable (Translation of Regi |
|
| March 19, 2015 |
Innocoll Holdings FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2015 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Innocoll AG Unit 9, Block D Monksland Business Park Monksland, Athlone Ireland ( |
|
| March 19, 2015 |
Innocoll AG Announces Fourth Quarter and Full Year 2014 Financial and Operating Results Exhibit 99.1 Innocoll AG Announces Fourth Quarter and Full Year 2014 Financial and Operating Results ATHLONE, IRELAND?March 19, 2015?Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating r |
|
| March 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| December 19, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| December 8, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| December 8, 2014 |
Exhibit 99.1 Innocoll AG Appoints Tony Zook as Chief Executive Officer as Company Progresses Toward Becoming a Fully-Integrated Commercial Company Michael Myers Appointed as Head of Portfolio Operations to Continue Guiding Late-Stage Clinical Programs ATHLONE, IRELAND—December 8, 2014—Innocoll AG (Nasdaq: INNL) today announced that Tony Zook, formerly executive vice president, Global Commercial Op |
|
| December 4, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| November 13, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| November 13, 2014 |
INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME/(LOSS) (UNAUDITED) EX-99.1 2 t1402202ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 INNOCOLL AG CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME/(LOSS) (UNAUDITED) Thousands of Euros (except share and share data) Notes Three months ended 09/30/2014 Three months ended 09/30/2013 Nine months ended 09/30/2014 Nine months ended 09/30/2013 Revenue 4 € 1,141 € 627 € 3,742 € 2,712 Cost of sales (1,218 ) (879 ) (4,161 ) (3,03 |
|
| November 13, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| November 13, 2014 |
Innocoll AG Announces Third Quarter 2014 Financial and Operating Results Exhibit 99.1 Innocoll AG Announces Third Quarter 2014 Financial and Operating Results ATHLONE, IRELAND—Nov. 13, 2014—Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced financial and operating results for the t |
|
| October 22, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath |
|
| October 22, 2014 |
Exhibit 99.2 Innocoll AG, Saal an der Donau - ISIN DE000A12UKR1 - - Securities identification number A12UKR - Our shareholders are hereby invited to participate in the Extraordinary General Meeting scheduled for Thursday, 4th December 2014 at 2 p.m. CET in the offices of Dr. Susanne Frank, Residenzstraße 27, 80333 Munich, Germany I. Agenda 1. Resolution on the authorization to grant subscription r |
|
| October 22, 2014 |
Innocoll AG Proposes Changes to Supervisory Board and Stock Option Plan EX-99.1 2 t1401996ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Innocoll AG Proposes Changes to Supervisory Board and Stock Option Plan ATHLONE, IRELAND—October 22, 2014—Innocoll AG (Nasdaq: INNL), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today posted |
|
| September 12, 2014 |
Articles of Association Convenience Translation EX-3.1 2 t1401702ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 Satzung Articles of Association Convenience Translation I. ALLGEMEINE BESTIMMUNGEN I. GENERAL PROVISIONS § 1 Firma, Sitz Section 1 Corporate Name, Registered Office 1. Die Gesellschaft führt die Firma 1. The name of the Company is Innocoll AG. Innocoll AG. 2. Die Gesellschaft hat ihren Sitz in Saal an der Donau. 2. The Company has its registered o |
|
| September 12, 2014 |
INNL / Innocoll Holdings plc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2014 Commission File Number: 001-36565 INNOCOLL AG (Exact Name of Registrant as Specified in Its Charter) Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeat |
|
| August 13, 2014 |
INNL / Innocoll Holdings plc / MORGAN STANLEY - SC 13D/A Activist Investment SC 13D/A CUSIP No. 45780Q103 13D Page 1 of 11 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) INNOCOLL AG (Name of Issuer) American Depositary Shares, eac |
|
| August 13, 2014 |
EX-99.B EXHIBIT B - LEGAL PROCEEDINGS Unless the context otherwise requires, the term “Morgan Stanley” means Morgan Stanley and its consolidated subsidiaries. Morgan Stanley & Co. LLC (“MS&Co.”) and Morgan Stanley Smith Barney LLC (“MSSB LLC”), referenced below, are Morgan Stanley’s primary U.S. broker-dealers. (a) On September 30, 2009, Morgan Stanley entered into an administrative settlement agr |
|
| August 13, 2014 |
EX-99.A EXHIBIT A – JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d–1(k)(l) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect t |
|
| August 12, 2014 |
INNL / Innocoll Holdings plc / Fortress Investment Group LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 INNOCOLL AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 nom |
|
| August 12, 2014 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 - JOINT FILLING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This JOINT FILING AGREEMENT, dated as of August 11, 2014, is entered into by and among Cam Investment Cayman Holdings L.P., Cam Investment Cayman Holdings GP Inc., Hybrid GP Holdings LLC, FIG LLC, Fortress Operating Entity I LP, FIG Corp., and Fortress Investment Group LLC. Each of the above are collect |
|
| August 11, 2014 |
EX-99.A EXHIBIT A – JOINT FILING AGREEMENT JOINT FILING AGREEMENT In accordance with Rule 13d–1(k)(l) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) with respect t |
|
| August 11, 2014 |
EX-99.B EXHIBIT B - LEGAL PROCEEDINGS Unless the context otherwise requires, the term “Morgan Stanley” means Morgan Stanley and its consolidated subsidiaries. Morgan Stanley & Co. LLC (“MS&Co.”) and Morgan Stanley Smith Barney LLC (“MSSB LLC”), referenced below, are Morgan Stanley’s primary U.S. broker-dealers. (a) On September 30, 2009, Morgan Stanley entered into an administrative settlement agr |
|
| August 11, 2014 |
INNL / Innocoll Holdings plc / MORGAN STANLEY - SCHEDULE 13D Activist Investment Schedule 13D CUSIP No. 45780Q103 13D Page 1 of 11 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 INNOCOLL AG (Name of Issuer) American Depositary Shares, each representing |
|
| August 4, 2014 |
INNL / Innocoll Holdings plc / Investment Partners, L.P. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Innocoll AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 nominal value per share (Title of Class of Securities) 45780Q103 (CUSIP Number) Paul Oxholm Investment Partners, L.P. 855 Berkshire Boulevard, Sui |
|
| August 4, 2014 |
SC 13D 1 v385591sc13d.htm FORM SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Innocoll AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 nominal value per sha |
|
| August 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Innocoll AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 nominal value per share (Title of Class of Securities) 45780Q103 (CUSIP Number) Ron Carlson, Esq. NewSmith Opportunities Private Equity Fund L.P. |
|
| August 4, 2014 |
INNL / Innocoll Holdings plc / Big Creek, L.P. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Innocoll AG (Name of Issuer) American Depositary Shares, each representing 1/13.25 of an Ordinary Share Ordinary Shares, €1.00 nominal value per share (Title of Class of Securities) 45780Q103 (CUSIP Number) Paul Oxholm Big Creek, L.P. 855 Berkshire Boulevard, Suite 103 Wyo |
|
| July 29, 2014 |
INNL / Innocoll Holdings plc POS EX - - POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on July 29, 2014 Registration No. 333-196910 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into Engli |
|
| July 29, 2014 |
Articles of Association Convenience Translation Exhibit 3.1 Satzung Articles of Association Convenience Translation I. ALLGEMEINE BESTIMMUNGEN I. GENERAL PROVISIONS § 1 Firma, Sitz Section 1 Corporate Name, Registered Office 1. Die Gesellschaft führt die Firma 1. The name of the Company is Innocoll AG. Innocoll AG. 2. Die Gesellschaft hat ihren Sitz in Saal an der Donau. 2. The Company has its registered office at Saal an der Donau. § 2 Gegenst |
|
| July 25, 2014 |
6,500,000 American Depositary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-196910 6,500,000 American Depositary Shares Representing 490,567 Ordinary Shares Innocoll AG $9.00 per American Depositary Share • Innocoll AG, a German stock corporation, is offering 6,500,000 American Depositary Shares, or ADSs. Each ADS will represent 1/13.25 ordinary shares with a notional value of €1.00 per share. • T |
|
| July 25, 2014 |
INNL / Innocoll Holdings plc POS AM - - POST-EFFECTIVE AMENDMENT NO.1 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on July 25, 2014 Registration No. 333-196910 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into Engli |
|
| July 25, 2014 |
INNOCOLL AG Free Writing Prospectus FWP 1 t1401378fwp.htm FREE WRITING PROSPECTUS Issuer Free Writing Prospectus dated July 24, 2014 Relating to Preliminary Prospectus dated July 24, 2014 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration No. 333-196910 INNOCOLL AG Free Writing Prospectus This free writing prospectus relates to the initial public offering of American Depositary Shares (the "ADSs") of Innocoll AG a |
|
| July 24, 2014 |
Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. |
|
| July 24, 2014 |
INNL / Innocoll Holdings plc F-1/A - - AMENDMENT NO. 3 TO FORM F-1 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 24, 2014 Registration No. 333-196910 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into En |
|
| July 24, 2014 |
INNL / Innocoll Holdings plc CORRESP - - July 24, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Innocoll AG Registration Statement on Form F-1 File No. 333-196910 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Innocoll AG (the “Registrant”) hereby requests, subject to telephone |
|
| July 24, 2014 |
LICENSING, MANUFACTURING AND SUPPLY AGREEMENT EX-10.2 7 t1401322ex10-2.htm EXHIBIT 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] Exhibit 10.2 LICENSING, MANUFACTURING AND SUPPLY AGREEMENT This Licensing, Manufacturing and Supply Agreement |
|
| July 24, 2014 |
Exhibit 10.7 INNOCOLL AG SOFINNOVA VENTURE PARTNERS VIII, L.P. CERTAIN SHAREHOLDERS OF INNOCOLL AG SUPERVISORY BOARD MEMBER NOMINATION AND VOTING AGREEMENT DATED JULY [●], 2014 TABLE OF CONTENTS SECTION PAGE 1. Interpretation and Definitions 1 2. Nomination and election of Board Member 3 3. Representations 5 4. Termination of the Agreement 5 5. Notices 6 6. Amendment; Waiver 6 7. Further Assurance |
|
| July 24, 2014 |
EX-4.1 2 t1401322ex4-1.htm EXHBIT 4.1 Exhibit 4.1 WKN: A12UKR Innocoll AG ISIN: DE000A12UKR mit Sitz in Saal an der Donau Ordnungs-Nr. 001 Globalurkunde über bis zu [·] auf den Namen der Citigroup Global Markets Deutschland AG, Frankfurt am Main, lautende Stammaktien in Form von Stückaktien Aktiennummern 1 bis [·] Die Anzahl der in dieser Globalurkunde verbrieften und begebenen Aktien ergibt sich |
|
| July 24, 2014 |
INNL / Innocoll Holdings plc CORRESP - - [CITIBANK LETTERHEAD] July 24, 2014 Via EDGAR and Telecopier Securities and Exchange Commission 100 F Street, N. |
|
| July 24, 2014 |
INNL / Innocoll Holdings plc CORRESP - - July 24, 2014 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Innocoll AG Registration Statement on Form F-1 File No. 333-196910 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Innocoll AG (the “Registrant”) hereby requests, subject to telephone |
|
| July 24, 2014 |
EUSA PHARMA (EUROPE) LIMITED — and — INNOCOLL PHARMACEUTICALS LIMITED, — and — SYNTACOLL AG Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. |
|
| July 24, 2014 |
LICENSING, MANUFACTURING AND SUPPLY AGREEMENT Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. |
|
| July 24, 2014 |
EXCLUSIVE DISTRIBUTION AGREEMENT Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. |
|
| July 24, 2014 |
by and among INNOCOLL AG CITIBANK, N.A., as Depositary, Exhibit 4.2 DEPOSIT AGREEMENT by and among INNOCOLL AG AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [DATE], 2014 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 2 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Section 1.4 “American Depo |
|
| July 24, 2014 |
INNL / Innocoll Holdings plc F-1/A - - AMENDMENT NO. 2 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on July 24, 2014 Registration No. 333-196910 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Federal Rep |
|
| July 24, 2014 |
MANUFACTURING AND SUPPLY AGREEMENT Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. |
|
| July 23, 2014 |
INNL / Innocoll Holdings plc 8-A12B - - FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 INNOCOLL AG (Exact name of registrant as specified in its charter) Federal Republic of Germany Not Applicable (State or other jurisdiction of Incorporation) (I. |
|
| July 17, 2014 |
Very truly yours, PATTERSON BELKNAP WEBB & TYLER LLP By: /s/ Herman H. Raspé A Member of the Firm Exhibit (d) July 17, 2014 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Unite |
|
| July 17, 2014 |
As filed with the Securities and Exchange Commission on July 17, 2014 Registration No. |
|
| July 17, 2014 |
Exhibit (a) DEPOSIT AGREEMENT by and among INNOCOLL AG AND CITIBANK, N.A., as Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [DATE], 2014 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 2 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Section 1.4 “American Depo |
|
| July 15, 2014 |
EX-10.10 9 t1401138ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 Phantom Share Award Agreement between 1. Innocoll AG registered with the commercial register of the local court of Regensburg under HRB 14298, (the “Company”), and 2. [Name, address] (the “Grantee”). The Company and the Grantee are each hereinafter individually referred to as a “Party” and together also as the “Parties”. Section 1 Prelimin |
|
| July 15, 2014 |
Exhibit 16.1 KPMG Audit 1 Stokes Place St. Stephen’s Green Dublin 2 Ireland 8 July 2014 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Innocoll GmbH prior to their registration. On February 6, 2014, we resigned. We have read Innocoll GmbH’s statements regarding the change in certifying accountant included in its Registra |
|
| July 15, 2014 |
Exhibit 8.3 Our Ref 017340.0031.SM July 15, 2014 Innocoll AG Midlands Innovation and Research Centre Dublin Road Athlone County Westmeath Ireland Innocoll AG (the “Company”) Dear Sirs, 1. Capacity and Basis We have acted as Irish solicitors for the Company in connection with the initial public offering by the Company of certain American Depository Shares (“ADSs”) in the capital of the Company (the |
|
| July 15, 2014 |
Exhibit 10.9 Award Agreement between 1. Innocoll AG, registered with the commercial register of the local court of Regensburg under HRB 14298, (the “Company”), and 2. [Name, address] (the “Grantee”). The Company and the Grantee are each hereinafter individually referred to as a “Party” and together also as the “Parties”. Section 1 Preliminary Remarks 1. The nominal share capital of the Company (Gr |
|
| July 15, 2014 |
Exhibit 3.2 Geschäftsordnung für den Aufsichtsrat der Innocoll AG Rules of Procedure of the Supervisory Board of Innocoll AG Der Aufsichtsrat der Innocoll AG (nachfolgend die „Gesellschaft“) hat durch Beschluss vom 24. Juni 2014 seine Geschäftsordnung wie folgt festgestellt: By way of a resolution dated 24 June 2014, the supervisory board of Innocoll AG (hereinafter the “Company”) has adopted the |
|
| July 15, 2014 |
Dem Chief Executive Officer (CEO) werden folgende Aufgaben zugewiesen: EX-3.3 4 t1401138ex3-3.htm EXHIBIT 3.3 Exhibit 3.3 Geschäftsordnung für den Vorstand der Innocoll AG Rules of Procedure of the Management Board of Innocoll AG Aufgrund § 5 Abs. 3 der Satzung der Innocoll AG und des Aufsichtsratsbeschlusses vom 24. Juni 2014 wird die folgende Geschäftsordnung für den Vorstand der Innocoll AG in Kraft gesetzt: In accordance with Section 5 para. 3 of the articles of |
|
| July 15, 2014 |
Exhibit 10.8 OPTION AGREEMENT Dated as of [•], 2014 between 1. Innocoll AG, a stock corporation under German law, registered with the commercial register at the Local Court of Regensburg under HRB 14298 (the “Company”), and the Shareholders, as listed, 2. Rolf D. Schmidt, 205 Sweitzer Rd, Sinking Spring PA 19608, USA, 3. Big Creek L.P., 855 Berkshire Blvd, Suite 103 Wyomissing, PA 19610-1225, USA, |
|
| July 15, 2014 |
EX-3.1 2 t1401138ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 Satzung Articles of Association Convenience Translation I. ALLGEMEINE BESTIMMUNGEN I. GENERAL PROVISIONS § 1 Firma, Sitz Section 1 Corporate Name, Registered Office 1. Die Gesellschaft führt die Firma Innocoll AG. 1. The name of the Company is Innocoll AG. 2. Die Gesellschaft hat ihren Sitz in Saal an der Donau. 2. The Company has its registered o |
|
| July 15, 2014 |
INNL / Innocoll Holdings plc F-1/A - - AMENDMENT NO. 1 TO FORM F-1 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 15, 2014 Registration No. 333-196910 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL AG (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into En |
|
| July 14, 2014 |
INNL / Innocoll Holdings plc CORRESP - - begin 644 filename2.pdf M)5!$1BTQ+C4-)>+CS],-"C,P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,S(@,"!O8FH-/#PO07)T0F]X6SD@,3@@ M-C`S(#%LY(#D@-C`S(#19SR7 MX+@1\^$"] M-$ZSX2P<:1[DBI6QQ`6Z`2N$[OX^'2V*P;`("UXS&$I6D=<,AC:K6:[IITF! MZ;YD)7FV;[->IN>P)J;GLNQRPWF6CH:ZN*;SPSY=ZD5QL[]31][O6Z8Z[&` MFEAWDXS"Q2=UJ8#+W[:2Q54V:2Y8.27-(#B'S"?K$ MD)M`LQ0Z:FCY`J4;@"$2N<\P`!VA6')`9@S!*46T |
|
| July 14, 2014 |
INNL / Innocoll Holdings plc CORRESP - - Jeffrey A. Baumel Partner [email protected] D +1 212 768 5374 Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 USA T +1 212 768 6700 F +1 212 768 6800 July 14, 2014 Mr. Jeffrey P. Riedler Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Innocoll AG Registration Statement on Form F-1 File No. 333-196910 |
|
| July 10, 2014 |
INNL / Innocoll Holdings plc CORRESP - - Jeffrey A. Baumel Partner [email protected] D +1 212 768 5374 Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 USA T +1 212 768 6700 F +1 212 768 6800 July 10, 2014 Mr. Jeffrey P. Riedler Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Innocoll GmbH Registration Statement on Form F-1 Filed June 19, 20 |
|
| July 10, 2014 |
INNL / Innocoll Holdings plc CORRESP - - begin 644 filename2.pdf M)5!$1BTQ+C4-)>+CS],-"C,R(#`@;V)J#3P\+TQI;F5A@`D&`-!Q!<@P78&2$@?!4DT@XA6(,&\`,0*`+$V`@F)SR#%72"QFR"Q M5R""'<0U`Q+<+2`N+XCE`20FKV=@8F0`$@P,#(P4$?\9SW\&"#``D1$0/0T* M96YD%LY(#D@-C`S(#%LP(#`@-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,S4@ M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9ILE=.M5B M-]CUZ63L]GIPLBY.PR(J:,YIR`D+S3D-!>$IYPQT6N#G`2<]22>6 MTZXS/0Y5\0#7QP.X5>OBL==[@/-^RC*U81A,#CO\0%"M8RRJ(A |
|
| July 3, 2014 |
INNL / Innocoll Holdings plc CORRESP - - Jeffrey A. Baumel Partner [email protected] D +1 212 768 5374 Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 USA T +1 212 768 6700 F +1 212 768 6800 July 3, 2014 FOIA Confidential Treatment Request The entity requesting confidential treatment is Innocoll GmbH Midlands Innovation and Research Centre Dublin Road, Athlone County Westmeath Ireland Telephone: +353 (0) 90 6 |
|
| June 19, 2014 |
Exhibit 10.18 THIS LICENCE is made the 24th day of November 2008 BETWEEN THE GRANTOR of the One Part and THE LICENSEE of the Other Part. NOW IT IS HEREBY AGREED as follows:- Definitions 1. In this Licence where the context so admits :- The following expressions shall have the following meaning :- “the Grantor” is Athlone Institute of Technology, Dublin Road, Athlone, Co. Westmeath. “the Licensee” |
|
| June 19, 2014 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on June 19, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL GmbH (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Federal Rep |
|
| June 19, 2014 |
LICENSING, MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.6 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] LICENSING, MANUFACTURING AND SUPPLY AGREEMENT This Licensing, Manufacturing and Supply Agreement (the “Agreement”) is being entered into as |
|
| June 19, 2014 |
[FORM OF OPINION FROM WILLIAM FRY] Exhibit 8.3 [FORM OF OPINION FROM WILLIAM FRY] Our Ref 017340.0031.SM [●] June 2014 Innocoll AG Midlands Innovation and Research Centre Dublin Road Athlone County Westmeath Ireland Innocoll AG (the “Company”) Dear Sirs, 1. Capacity and Basis We have acted as Irish solicitors for the Company in connection with the initial public offering by the Company of certain American Depository Shares (“ADSs”) |
|
| June 19, 2014 |
Exhibit 10.17 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] Lease 4/2009 between Karl Sipmeier Fliederstraße 1 93342 Saal an der Donau (Steuer-Nr. 126/274/70167) -Owner and Company Syntacoll GmbH re |
|
| June 19, 2014 |
Exhibit 21.1 List of Subsidiaries Innocoll, Inc., a Delaware corporation Innocoll Pharmaceuticals Ltd., an Irish private limited company Innocoll Technologies Ltd., an Irish private limited company Syntacoll GmbH, a German limited liability company (wholly-owned subsidiary of Innocoll Pharmaceuticals Ltd.) |
|
| June 19, 2014 |
Exhibit 10.14 AGREEMENT In consideration of her employment by INNOCOLL, INC. (“Company”) and the compensation and benefits outlined below, and intending to be legally bound, DENISE P. CARTER (“Executive”) agrees as follows: 1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 1.1 An “Affiliate” of any Person means any Person directly or indirectly |
|
| June 19, 2014 |
EXCLUSIVE DISTRIBUTION AGREEMENT EX-10.3 9 t1401045ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] EXCLUSIVE DISTRIBUTION AGREEMENT This EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”) is made |
|
| June 19, 2014 |
EX-10.12 14 t1401045ex10-12.htm EXHIBIT 10.12 Exhibit 10.12 MIRC, Dublin Road Athlone Co. Westmeath, Ireland Tel: + 353 (0)90 6486834 Fax: + 353 (0)90 6486835 www. innocoll-pharma.com Gordon Dunn 111 Abingdon Road London W8 6QU 1 June, 2013 Dear Mr. Dunn, On behalf of Innocoll Pharmaceuticals Ltd (the “Company”), I am very pleased to confirm your employment by the Company. Your employment will be |
|
| June 19, 2014 |
Exhibit 10.16 CONTRACT OF EMPLOYMENT made between Syntacoll GmbH, Donaustraße 24, 93342 Saal an der Donau - hereinafter referred to as “GmbH” - and Dr. Alexandra Timm, Beim Roten Kreuz 14, 93057 Regensburg - hereinafter referred to as “employee” - §1 Status (1) The employee has been appointed to sole director by resolution of the shareholders. The employee is entitled to represent the company as t |
|
| June 19, 2014 |
MANUFACTURING AND SUPPLY AGREEMENT EX-10.5 11 t1401045ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] MANUFACTURING AND SUPPLY AGREEMENT This Manufacturing and Supply Agreement (the “Agreement”) is |
|
| June 19, 2014 |
Exhibit 10.4 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] Execution Version April 27, 2010 EUSA PHARMA (EUROPE) LIMITED — and — INNOCOLL PHARMACEUTICALS LIMITED, — and — SYNTACOLL AG Amended and Re |
|
| June 19, 2014 |
Exhibit 1.1 Innocoll AG Registered Ordinary Shares in the form of American Depositary Shares (each representing one Ordinary Share, no par value, with a notional par value of €1.00 per Ordinary Share) UNDERWRITING AGREEMENT [·], 2014 PIPER JAFFRAY & CO. STIFEL NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters listed in Schedule I hereto c/o Piper Jaffray & Co. 800 Nic |
|
| June 19, 2014 |
CORRESP 35 filename35.htm Jeffrey A. Baumel Partner [email protected] D +1 212 768 5374 Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 USA T +1 212 768 6700 F +1 212 768 6800 June 19, 2014 Mr. Jeffrey P. Riedler Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Innocoll GmbH Amendment No. 1 to Draft R |
|
| June 19, 2014 |
Exhibit 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] LICENSING, MANUFACTURING AND SUPPLY AGREEMENT This Licensing, Manufacturing and Supply Agreement (the “Agreement”) is being entered into as |
|
| June 19, 2014 |
Exhibit 10.15 EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of August 21, 2009, between Innocoll Holdings, Inc., a Delaware corporation or its assignee (the “Company”), and James Croke, a resident of Ireland (the “Employee”). Background A. The Company wishes to employ the Employee and the Employee wishes to be employed by the Company, subject to the terms and conditions set forth in this Agreement |
|
| June 19, 2014 |
Exhibit 10.13 EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of January 12, 2004, between Innocoll, Inc., a Delaware corporation with its registered office located at 103 Springer Building, 3411 Silverside Road, Wilmington, Delaware 19810 or its assignee (the “Company”), and David Prior, an individual residing at 1B Cumberland Close, Ruddington, Nottingham, NG11 6PH UK (the “Employee”), Background |
|
| June 19, 2014 |
Exhibit 10.11 AGREEMENT In consideration of his employment by INNOCOLL, INC. (“Company”) and the compensation and benefits outlined below, and intending to be legally bound, MICHAEL MYERS, Ph.D. (“Executive”) agrees with Company as follows: 1. Definitions. As used in this Agreement, the following terms whether used in the singular or plural form shall have the meanings set forth below: 1.1 An “Aff |
|
| June 19, 2014 |
Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential portions are marked: [ *** ] LICENSE AND SUPPLY AGREEMENT This License and Supply Agreement (the “Agreement”) is being entered into as of the 14th day of August 2013 (t |
|
| May 13, 2014 |
TABLE OF CONTENTS This registrant is submitting this Amendment No. 1 to the draft registration statement as an “emerging growth company” pursuant to Section 6(e) of the Securities Act of 1933, as amended. As confidentially submitted to the U.S. Securities and Exchange Commission on May 13, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM |
|
| May 13, 2014 |
Exhibit 21.1 List of Subsidiaries Innocoll, Inc., a Delaware corporation Innocoll Pharmaceuticals Ltd., an Irish private limited company Innocoll Technologies Ltd., an Irish private limited company Syntacoll GmbH, a German limited liability company (wholly-owned subsidiary of Innocoll Pharmaceuticals Ltd.) |
|
| May 13, 2014 |
Jeffrey A. Baumel Partner [email protected] D +1 212 768 5374 Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 USA T +1 212 768 6700 F +1 212 768 6800 May 13, 2014 Mr. Jeffrey P. Riedler Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Innocoll GmbH Draft Registration Statement on Form F-1 Submitted Ma |
|
| March 26, 2014 |
EX-10.17 8 filename8.htm Exhibit 10.17 THIS LICENCE is made the 24th day of November 2008 BETWEEN THE GRANTOR of the One Part and THE LICENSEE of the Other Part. NOW IT IS HEREBY AGREED as follows:- Definitions 1. In this Licence where the context so admits :- The following expressions shall have the following meaning :- “the Grantor” is Athlone Institute of Technology, Dublin Road, Athlone, Co. W |
|
| March 26, 2014 |
Exhibit 10.10 AGREEMENT In consideration of his employment by INNOCOLL, INC. (“Company”) and the compensation and benefits outlined below, and intending to be legally bound, MICHAEL MYERS, Ph.D. (“Executive”) agrees with Company as follows: 1. Definitions. As used in this Agreement, the following terms whether used in the singular or plural form shall have the meanings set forth below: 1.1 An “Aff |
|
| March 26, 2014 |
EX-10.11 3 filename3.htm Exhibit 10.11 MIRC, Dublin Road Athlone Co. Westmeath, Ireland Tel: + 353 (0)90 6486834 Fax: + 353 (0)90 6486835 www. innocoll-pharma.com Gordon Dunn 111 Abingdon Road London W8 6QU 1 June, 2013 Dear Mr. Dunn, On behalf of Innocoll Pharmaceuticals Ltd (the “Company”), I am very pleased to confirm your employment by the Company. Your employment will be subject to the terms |
|
| March 26, 2014 |
Exhibit 10.12 EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of January 12, 2004, between Innocoll, Inc., a Delaware corporation with its registered office located at 103 Springer Building, 3411 Silverside Road, Wilmington, Delaware 19810 or its assignee (the “Company”), and David Prior, an individual residing at 1B Cumberland Close, Ruddington, Nottingham, NG11 6PH UK (the “Employee”), Background |
|
| March 26, 2014 |
TABLE OF CONTENTS As confidentially submitted to the U.S. Securities and Exchange Commission on March 26, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INNOCOLL GmbH (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into En |
|
| March 26, 2014 |
EX-10.13 5 filename5.htm Exhibit 10.13 AGREEMENT In consideration of her employment by INNOCOLL, INC. (“Company”) and the compensation and benefits outlined below, and intending to be legally bound, DENISE P. CARTER (“Executive”) agrees as follows: 1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 1.1 An “Affiliate” of any Person means any Pers |
|
| March 26, 2014 |
Exhibit 10.14 EMPLOYMENT AGREEMENT THIS AGREEMENT, dated as of August 21, 2009, between Innocoll Holdings, Inc., a Delaware corporation or its assignee (the “Company”), and James Croke, a resident of Ireland (the “Employee”). Background A. The Company wishes to employ the Employee and the Employee wishes to be employed by the Company, subject to the terms and conditions set forth in this Agreement |
|
| March 26, 2014 |
Exhibit 10.15 CONTRACT OF EMPLOYMENT made between Syntacoll GmbH, Donaustraße 24, 93342 Saal an der Donau - hereinafter referred to as “GmbH” - and Dr. Alexandra Timm, Beim Roten Kreuz 14, 93057 Regensburg - hereinafter referred to as “employee” - §1 Status (1) The employee has been appointed to sole director by resolution of the shareholders. The employee is entitled to represent the company as t |
